Clinical outcome measures and rating scales in multiple sclerosis trials.

In this review, we analyzed clinical outcome measures used in multiple sclerosis (MS) clinical trials in which the primary goal is to slow or arrest progression of disease. In addition, we examined rating scales that quantify symptomatic complications of MS (for example, spasticity) and the current role of magnetic resonance imaging in MS treatment trials. Each proposed scale has advantages and deficiencies, and none meets all the criteria for an ideal outcome measure. The validity of trial design may be improved by using combinations of selected components of current scales as well as new instruments targeted to specific variables (such as motor strength). Symptom-specific rating scales are most appropriately used in trials of symptomatic therapeutic strategies for MS. Until serial magnetic resonance imaging changes are definitely known to predict long-term impairment and disability in patients with MS, clinical outcome measures will remain the primary means of assessing therapeutic efficacy in phase III clinical trials.

[1]  P. Ketelaer,et al.  Pain in multiple sclerosis patients A prospective study using the Mc Gill Pain Questionnaire , 1986, Clinical Neurology and Neurosurgery.

[2]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[3]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[4]  W. Rymer,et al.  Spastic hypertonia: mechanisms and measurement. , 1989, Archives of physical medicine and rehabilitation.

[5]  B. Pentland,et al.  Inter‐rater reliability of the modified Ashworth Scale for spasticity in hemiplegic patients , 1992, International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation.

[6]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[7]  J. Fisk,et al.  The Impact of Fatigue on Patients with Multiple Sclerosis , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[9]  E. Kaplan,et al.  Guidelines for neuropsychological research in multiple sclerosis. , 1990, Archives of neurology.

[10]  A V Swan,et al.  An assessment of disability rating scales used in multiple sclerosis. , 1991, Archives of neurology.

[11]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[12]  R. Schiffer,et al.  Depressive episodes in patients with multiple sclerosis. , 1983, The American journal of psychiatry.

[13]  R. Joffe,et al.  Mood disorder and multiple sclerosis. , 1987, Archives of neurology.

[14]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[15]  G. Logroscino,et al.  Accuracy of self‐assessment of the minimal record of disability in patients with multiple sclerosis , 1993, Acta neurologica Scandinavica.

[16]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[17]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[18]  B. Weinshenker,et al.  Screening for Major Depression in the Early Stages of Multiple Sclerosis , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[19]  R. Farmer,et al.  Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. , 1992, Archives of neurology.

[20]  R. Kikinis,et al.  Longitudinal MRI in multiple sclerosis , 1994, Neurology.

[21]  George V. Kondraske,et al.  Neuroperformance Evaluation of Multiple Sclerosis Disease Progression in a Clinical Trial: Implications for Neurological Outcomes , 1993 .

[22]  J. Kurtzke,et al.  On the evaluation of disability in multiple sclerosis , 1961, Neurology.

[23]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[24]  P. McGrath,et al.  Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients , 1994, Pain.

[25]  D. Goodkin,et al.  Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. , 1990, Archives of neurology.

[26]  J. Gybels,et al.  Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[27]  K. Foley,et al.  Pain syndromes in multiple sclerosis , 1988, Neurology.

[28]  C. Poser,et al.  Cognitive function in patients with multiple sclerosis. , 1980, Archives of neurology.

[29]  C. Granger,et al.  Functional assessment scales: a study of persons with multiple sclerosis. , 1990, Archives of physical medicine and rehabilitation.

[30]  B. Ashworth.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. , 1964, The Practitioner.

[31]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[32]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[33]  W. Tourtellotte,et al.  QUANTITATIVE CLINICAL NEUROLOGICAL TESTING. II. SOME STATISTICAL CONSIDERATIONS OF A BATTERY OF TESTS. , 1965, Journal of chronic diseases.

[34]  Stephen M. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[35]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[36]  H. Weiner,et al.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.

[37]  G. Comi,et al.  Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis , 1993, Journal of the Neurological Sciences.

[38]  E J Orav,et al.  Disease Steps in multiple sclerosis , 1995, Neurology.

[39]  F. Lublin,et al.  Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial , 1994, Neurology.

[40]  R. Knobler,et al.  A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.

[41]  A. Alpérovitch,et al.  Validation of self-reported neurological disability in multiple sclerosis. , 1994, International Journal of Epidemiology.

[42]  M Filippi,et al.  A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis , 1995, Neurology.

[43]  D. Benson,et al.  Subcortical Dementia: Review of an Emerging Concept , 1984 .

[44]  J. Kurtzke,et al.  The Disability Status Scale for multiple sclerosis , 1989, Neurology.

[45]  C. Granger,et al.  The functional independence measure: a new tool for rehabilitation. , 1987, Advances in clinical rehabilitation.

[46]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[47]  S. Karlik,et al.  Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis , 1992, Annals of neurology.

[48]  J. Kurtzke.  A New Scale for Evaluating Disability in Multiple Sclerosis , 1955, Neurology.

[49]  W. Tourtellotte,et al.  QUANTITATIVE CLINICAL NEUROLOGICAL TESTING. I. A STUDY OF A BATTERY OF TESTS DESIGNED TO EVALUATE IN PART THE NEUROLOGICAL FUNCTION OF PATIENTS WITH MULTIPLE SCLEROSIS AND ITS USE IN A THERAPEUTIC TRIAL * , 1965, Annals of the New York Academy of Sciences.

[50]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[51]  J. Frank,et al.  The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.

[52]  A. Eisen,et al.  Electromyography in Disorders of Muscle Tone , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[53]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[54]  H. Tobi,et al.  Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.

[55]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[56]  R. Paul,et al.  Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) , 1995, Neurology.

[57]  D. Paty,et al.  Scales for rating impairment in multiple sclerosis , 1988, Neurology.

[58]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[59]  R W Bohannon,et al.  Variability and reliability of the pendulum test for spasticity using a Cybex II isokinetic dynamometer. , 1987, Physical therapy.

[60]  M. Clanet,et al.  Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences. , 1991, European neurology.

[61]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[62]  L. Fratiglioni,et al.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. , 1988, Archives of neurology.

[63]  S. Medendorp,et al.  Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis , 1995, Annals of neurology.

[64]  T. Bajd,et al.  Pendulum testing of spasticity. , 1984, Journal of biomedical engineering.

[65]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[66]  J. Baskerville,et al.  IDENTIFYING SUITABLE CANDIDATES FOR CLINICAL-TRIALS OF PROGRESSIVE MULTIPLE-SCLEROSIS , 1993 .